Mon to Fri 08h00 to 16h30 ( UTC +2)

Mon to Fri 08h00 to 16h30 ( UTC +2)

South Africa – The Value of a Patent in South Africa (Bayer Intellectual Property GmbH et al v Austell Pharmaceuticals (Pty) Ltd 20 May 2021 CCP

  1. Home
  2. /
  3. South Africa
  4. /
  5. South Africa – The Value of a Patent in South Africa (Bayer Intellectual Property GmbH et al v Austell Pharmaceuticals (Pty) Ltd 20 May 2021 CCP

Published Date: February 7, 2022

CLICK HERE TO VIEW JUDGEMENT

On 20 May 2021, the South African Patents Court confirmed the rights of a patentee in interim interdict proceedings in circumstances where the patent claim included a non-essential integer.

In this matter, and despite the constraints caused by the Covid-19 pandemic, detailed and voluminous affidavit evidence from various parties in different countries and lengthy legal argument, Bayer was able to obtain an interim interdict within less than 4 months of the launch of generic pharmaceutical being sold by the Austel Pharmaceuticals under the brand name, Rezalto.  This judgment confirms the value of a valid patent in South Africa and engenders confidence in the functioning of the South African intellectual property, legal and judicial systems.

Source:  PDF attached; 20210520 Bayer v Austel – Commissioner of Patents Judgement ZA2007-06238 – 20 May 2021 – OCR

How can we help you?

We have offices in Pretoria, Johannesburg, Cape Town, and Durban, please contact your nearest office for any legal enquiry or assistance.

Related News & Insights